BDNF modulated KCC2 ubiquitylation in spinal cord dorsal horn of mice

Juan-Juan Ma,Tian-Yu Zhang,Xin-Tong Diao,Lin Yao,Yin-Xia Li,Zhan-Wei Suo,Xian Yang,Xiao-Dong Hu,Yan-Ni Liu
DOI: https://doi.org/10.1016/j.ejphar.2021.174205
IF: 5.195
2021-09-01
European Journal of Pharmacology
Abstract:<p>The K<sup>+</sup>-Cl<sup>-</sup> co-transporter 2 (KCC2) is a neuron-specific Cl<sup>-</sup> extruder in the dorsal horn of spinal cord. The low intracellular Cl<sup>-</sup> concentration established by KCC2 is critical for GABAergic and glycinergic systems to generate synaptic inhibition. Peripheral nerve lesions have been shown to cause KCC2 dysfunction in adult spinal cord through brain-derived neurotrophic factor (BDNF) signaling, which switches the hyperpolarizing inhibitory transmission to be depolarizing and excitatory. However, the mechanisms by which BDNF impairs KCC2 function remain to be elucidated. Here we found that BDNF treatment enhanced KCC2 ubiquitination in the dorsal horn of adult mice, a post-translational modification that leads to KCC2 degradation. Our data showed that spinal BDNF application promoted KCC2 interaction with Casitas B-lineage lymphoma b (Cbl-b), one of the E3 ubiquitin ligases that are involved in the spinal processing of nociceptive information. Knockdown of Cbl-b expression decreased KCC2 ubiquitination level and attenuated the pain hypersensitivity induced by BDNF. Spared nerve injury significantly increased KCC2 ubiquitination, which could be reversed by inhibition of TrkB receptor. Our data implicated that KCC2 was one of the important pain-related substrates of Cbl-b and that ubiquitin modification contributed to BDNF-induced KCC2 hypofunction in the spinal cord.</p>
pharmacology & pharmacy
What problem does this paper attempt to address?